Biodel, NeurogesX blueprint IPO plans

Biodel has registered an IPO aimed at raising $86.2 million. The company is developing therapies for endocrine diseases such as diabetes and osteoporosis. Most of the money raised is earmarked for R&D.

NeurogesX has filed with the SEC to raise up to $69 million in an IPO. Dr. Wendye Robbins helped found the company in 2000, setting out to develop new therapies for neuropathc pain. NGX-4010 hit its primary endpoint for a Phase III trial last October. NGX-1991 is in Phase I, according to the company's Web site.

- here's the AP report on the Biodel IPO
- check out the release on NeurogesX
- read the MarketWatch report on NeurogesX

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.